Skip to NavigationSkip to content

study

Survey reveals over 2 million people impacted by long COVID in UK

Photo by Andrea Piacquadio from Pexels

A recent survey from Imperial College London has revealed that over 2 million people in the UK may have suffered from long lasting COVID-19 symptoms.

The REACT study, which was granted £5.5 million from the UK government, assessed self-reported data from 508,707 adults, finding that 5.8% of the whole study population had suffered from symptoms lasting over 12 weeks.

NICE guidelines on antidepressant withdrawal symptoms are misleading, study shows

Current NICE guidance concerning the severity of the effects of antidepressant withdrawal is misleading doctors according to research published in the journal Addictive Behaviours.

CBD dampens activity in brain regions associated with psychosis, study shows

Cannabidiol (CBD), one of the major constituents of cannabis, may be beneficial for patients with psychotic disorders due to its ability to modulate activity in brain regions associated with psychosis, a study published in the journal JAMA: Psychiatry has shown.

Eisai's weight loss drug lorcaserin found safe in major study

Eisai’s weight loss drug lorcaserin does not increase people’s risk of major cardiovascular events according to a study of 12,000 overweight and obese patients.

The study, which was funded by Eisai, tracked participants, all of whom had therosclerotic cardiovascular disease or multiple risk factors for heart disease, who were taking either lorcaserin or a placebo.  

The study found that there was no difference in the combined risk of heart disease between people taking lorcaserin and those taking a dummy pill.

Russian trolls spread vaccine misinformation on Twitter

Twitter bots and Russian trolls post content about vaccination at significantly higher rates than normal users, a new study has shown.

However the study, published in the American Journal of Public Health claims that content posted by Russian trolls “gives equal attention to both pro and anti-vaccine arguments”.

Letters to doctors reduce opioid prescriptions, study shows

A study has shown that Doctors who received a letter from the medical examiner’s office informing them of their patient’s fatal overdoses, prescribed fewer opioids.

In order to conduct the study, researchers involved used a database of 861 healthcare professionals who had prescribed opioids and other risky medications to those who had subsequently died of overdoses involving prescription medicines. More than 400 of those professionals listed on the database were sent so-called ‘Dear Doctor’ letters, through which they were informed that their patients had died of overdoses.

Merck says its Erbitux in combination with Folfox improves outcomes in colorectal cancer

Merck said late-stage trials for its Erbitux (cetuximab) in combination with Folfox significantly improved progression free survival in metastatic colorectal cancer (mCRC). 

The findings were announced at the ESMO 18th World Congress on Gastrointestinal Cancer (WCGC) and come from the pivotal Phase III study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer. 

Merck warned over missing Januvia safety study

Merck image

Merck has been warned by the FDA that it must carry out a post-marketing safety study on diabetes treatments Januvia and Janumet.

The company had agreed to conduct the study and submit to the regulator in June 2011, but missed this deadline, and repeatedly failed to make good on its promises to supply other data.

The US regulator demanded the study to assess the risk of acute pancreatitis, after 88 cases were reported in patients taking the drug between October 2006 and February 2009.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches